Tranzyme Pharma to Report First Quarter 2013 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report first quarter 2013 financial results after the close of the market on Thursday, May 9, 2013.
About Tranzyme Pharma
Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics. All of Tranzyme's (TZYM) drug discovery activities are based on its proprietary small molecule macrocyclic template chemistry (MATCH") technology, which has also been successfully used to generate drug candidates in partnership with other pharmaceutical companies. MATCH enables the rapid construct of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. By leveraging MATCH, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical need and continues to pursue funded drug discovery partnerships. Additional information on Tranzyme can be found at www.tranzyme.com .
CONTACT: Inquiries: Susan Sharpe Director, Corporate Communications (919) 328-1109 email@example.comSource: Tranzyme, Inc. 2013 GlobeNewswire, Inc.